Pular para o conteúdo

One-Shot Gene Therapies & Peptides | Longevity News Roundup—Week 31, 2026

31 de julho de 2026 · 30 min

Notas do episódio

Hosts:

Phil Newman: https://qrco.de/bgXpNY

Nina Patrick: ⁠⁠https://qrco.de/bgXpKn


----------

Sponsor: FlexBeam


FlexBeam is a wearable red light therapy system that brings targeted support directly to where you need it most. Lightweight, portable, and easy to use, it fits naturally into your daily routine, making recovery and self-care more accessible whether you're at home, traveling, or between activities.


Click the link below to learn more and use code LONGEVITY.TECHNOLOGY for 10% off.


Link: rechargehealthas.sjv.io/jRQyQ5


----------

In this week's Longevity News Roundup, Phil Newman and Nina Patrick examine new Alzheimer's therapies, the growing debate around experimental peptides, expanding access to investigational treatments, rapid advances in metabolic disease and encouraging progress in longevity gene therapy.


  • Voyager Therapeutics reported that its investigational gene therapy VY1706 reduced tau protein by up to 75% in non-human primates for six months after a single intravenous dose, using a novel blood-brain barrier delivery approach.
  • An advisory panel to the US Food and Drug Administration recommended broader access to compounded wellness peptides despite concerns over limited human evidence, highlighting the growing tension between consumer demand, regulatory oversight and the need for robust clinical trials.
  • Vandria announced that its oral mitochondrial therapy VNA-318 safely reached the brain in its first human study, supporting once-daily dosing ahead of planned Alzheimer's trials.
  • Montana advanced Right to Try legislation that could expand patient access to investigational therapies beyond traditional approval pathways, raising new questions about evidence, transparency and responsible implementation.
  • D&D Pharmatech reported that its once-weekly dual GLP-1/glucagon receptor agonist zabopegdutide rapidly reduced liver fat and stiffness, with benefits seen even among participants who experienced minimal weight loss.
  • Genflow Biosciences reported positive early results from its SIRT6 gene therapy trial in aging dogs, supporting the growing use of companion animals as a bridge toward future human longevity therapies


----------

News & References:


Todos os episódios de Longevity.Technology UNLOCKED

Configurações

Exibição

Idioma

Define quais estações você vê primeiro na página inicial.

Histórico

As rádios e episódios ouvidos recentemente e suas últimas buscas ficam só neste navegador.

Avisos

Um aviso rápido quando um podcast que você segue tem um episódio novo. Desative podcasts individuais pelo sino na página deles.

Conta

Salve favoritos – no app e no site.

Atalhos de teclado

/
Abrir busca
Espaço
Reproduzir ou pausar
← →
No player: voltar 15 s, avançar 30 s (episódios) · na fileira: próximo bloco
↑ ↓
Na fileira: alvo dentro do bloco
Home / End
Na fileira: primeiro ou último bloco
Esc
Fechar janela ou menu
?
Esta visão geral
Tocando agora

Ir para a estação

A seguir

    Adicione episódios com “A seguir” – eles tocam depois do episódio atual.